The emerging evidence suggests that the modulation of the ACE2/Ang-(1–7)/Mas receptor axis is a very attractive target in the therapy of the metabolic syndrome and diabetes-associated diseases affecting the heart and the kidney. This evidence concerns the gene ACE2 and diabetes mellitus.